AsianFin -- Chinese AI-driven drug discovery firm Insilico Medicine has completed a Phase IIa clinical trial for its candidate Rentosertib (ISM001-055), developed in collaboration with Beijing Union Medical College Hospital, aimed at treating idiopathic pulmonary fibrosis (IPF).

The trial, which enrolled 71 patients, demonstrated encouraging results. Patients receiving the drug showed improvements in forced vital capacity (FVC) compared to the placebo group, with the highest dose group experiencing an average increase of 98.4 milliliters. Most adverse events were mild to moderate, and serious adverse events were rare—supporting the drug’s safety profile.

Rentosertib is among the most advanced AI-discovered drug candidates globally, marking a major milestone in the application of artificial intelligence to pharmaceutical R&D. Insilico Medicine said the next step will involve larger-scale clinical trials to further confirm the drug’s efficacy and safety.